183 related articles for article (PubMed ID: 12023427)
1. Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone.
Croes EA; Roks G; Jansen GH; Nijssen PC; van Duijn CM
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):792-3. PubMed ID: 12023427
[TBL] [Abstract][Full Text] [Related]
2. Creutzfeldt-Jakob disease risk in Slovak recipients of human pituitary growth hormone.
Mitrova E; Belay G
Bratisl Lek Listy; 1999 Apr; 100(4):187-91. PubMed ID: 10914140
[TBL] [Abstract][Full Text] [Related]
3. Iatrogenic Creutzfeldt-Jakob disease following human growth hormone therapy: case report.
Caboclo LO; Huang N; Lepski GA; Livramento JA; Buchpiguel CA; Porto CS; Nitrini R
Arq Neuropsiquiatr; 2002 Jun; 60(2-B):458-61. PubMed ID: 12131950
[TBL] [Abstract][Full Text] [Related]
4. Human growth hormone-related iatrogenic Creutzfeldt-Jakob disease with abnormal imaging.
Lewis AM; Yu M; DeArmond SJ; Dillon WP; Miller BL; Geschwind MD
Arch Neurol; 2006 Feb; 63(2):288-90. PubMed ID: 16476821
[TBL] [Abstract][Full Text] [Related]
5. [Cerebral magnetic resonance imaging in iatrogenic Creutzfeldt-Jacob disease].
Gurau C; Zeghoudi AC; Atlaoui-Rabia S; Charitanski D; Mallecourt J
Presse Med; 2005 Sep; 34(15):1080-1. PubMed ID: 16334885
[TBL] [Abstract][Full Text] [Related]
6. Prion strains associated with iatrogenic CJD in French and UK human growth hormone recipients.
Douet JY; Huor A; Cassard H; Lugan S; Aron N; Mesic C; Vilette D; Barrio T; Streichenberger N; Perret-Liaudet A; Delisle MB; Péran P; Deslys JP; Comoy E; Vilotte JL; Goudarzi K; Béringue V; Barria MA; Ritchie DL; Ironside JW; Andréoletti O
Acta Neuropathol Commun; 2021 Aug; 9(1):145. PubMed ID: 34454616
[TBL] [Abstract][Full Text] [Related]
7. A case of Creutzfeldt-Jakob disease following cataract surgery: sporadic versus iatrogenic cause.
Gnanajothy R; Umashanker D; Vega MC; Wu BJ
Conn Med; 2013; 77(6):335-7. PubMed ID: 23923250
[TBL] [Abstract][Full Text] [Related]
8. Iatrogenic Creutzfeldt-Jakob disease.
Kobayashi A; Kitamoto T; Mizusawa H
Handb Clin Neurol; 2018; 153():207-218. PubMed ID: 29887137
[TBL] [Abstract][Full Text] [Related]
9. Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?
Boyd A; Klug GM; Schonberger LB; McGlade A; Brandel JP; Masters CL; Collins SJ
Med J Aust; 2010 Sep; 193(6):366-9. PubMed ID: 20854243
[TBL] [Abstract][Full Text] [Related]
10. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France.
Huillard d'Aignaux J; Costagliola D; Maccario J; Billette de Villemeur T; Brandel JP; Deslys JP; Hauw JJ; Chaussain JL; Agid Y; Dormont D; Alpérovitch A
Neurology; 1999 Oct; 53(6):1197-201. PubMed ID: 10522872
[TBL] [Abstract][Full Text] [Related]
11. A statistical model to identify the contaminated lots implicated in iatrogenic transmission of Creutzfeldt-Jakob disease among French human growth hormone recipients.
Huillard d'Aignaux J; Alpérovitch A; Maccario J
Am J Epidemiol; 1998 Mar; 147(6):597-604. PubMed ID: 9521187
[TBL] [Abstract][Full Text] [Related]
12. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States.
Fradkin JE; Schonberger LB; Mills JL; Gunn WJ; Piper JM; Wysowski DK; Thomson R; Durako S; Brown P
JAMA; 1991 Feb; 265(7):880-4. PubMed ID: 1992185
[TBL] [Abstract][Full Text] [Related]
13. Creutzfeldt-Jakob disease with unusually extensive neuropathology in a child treated with native human growth hormone.
Mikol J; Deslys JP; Zou WQ; Xiao W; Brown P; Budka H; Goutieres F
Clin Neuropathol; 2012; 31(3):127-34. PubMed ID: 22551916
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK.
Ritchie DL; Adlard P; Peden AH; Lowrie S; Le Grice M; Burns K; Jackson RJ; Yull H; Keogh MJ; Wei W; Chinnery PF; Head MW; Ironside JW
Acta Neuropathol; 2017 Aug; 134(2):221-240. PubMed ID: 28349199
[TBL] [Abstract][Full Text] [Related]
15. [Iatrogenic Creutzfeld-Jakob disease. Significance of cases observed after extracted growth hormone treatment].
Billette de Villemeur T
Rev Neurol (Paris); 1998 Oct; 154(10):651-2. PubMed ID: 9846334
[No Abstract] [Full Text] [Related]
16. A nationwide cohort study on Creutzfeldt-Jakob disease among human growth hormone recipients.
Wientjens DP; Rikken B; Wit JM; Hofman A; Stricker BH
Neuroepidemiology; 2000; 19(4):201-5. PubMed ID: 10859499
[TBL] [Abstract][Full Text] [Related]
17. Iatrogenic Creutzfeldt-Jakob disease.
Rappaport EB
Neurology; 1987 Sep; 37(9):1520-2. PubMed ID: 3306455
[TBL] [Abstract][Full Text] [Related]
18. Creutzfeldt-Jakob disease via dural and corneal transplants.
Lang CJ; Heckmann JG; Neundörfer B
J Neurol Sci; 1998 Oct; 160(2):128-39. PubMed ID: 9849795
[TBL] [Abstract][Full Text] [Related]
19. Iatrogenic Creutzfeldt-Jakob disease from commercial cadaveric human growth hormone.
Appleby BS; Lu M; Bizzi A; Phillips MD; Berri SM; Harbison MD; Schonberger LB
Emerg Infect Dis; 2013 Apr; 19(4):682-4. PubMed ID: 23750511
[No Abstract] [Full Text] [Related]
20. [Creutzfeldt-Jakob disease in a dura transplant recipient: first observation in Austria].
Radbauer C; Hainfellner JA; Gaudernak T; Deecke L; Budka H
Wien Klin Wochenschr; 1998 Jul; 110(13-14):496-500. PubMed ID: 9746964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
